Skip to search formSkip to main contentSkip to account menu

orlistat

Known as: (-)-Tetrahydrolipstatin, Orlipastat, tetrahydrolipastatin 
A reversible active-site inhibitor of gastrointestinal lipases. Orlistat forms a covalent bond with the active serine site in gastric and pancreatic… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Aim. To study the dynamics of cardiovascular risk factors in younger patients with obesity at the background of orlistat… 
2015
2015
Anorexia nervosa (AN), bulimia nervosa (BN) and obesity are eating disorders (ED) are considered to be mental illness, while… 
2014
2014
Background: The prevalence of obesity is increasing rapidly and, has largely been attributed to increased dietary intake of high… 
2012
2012
Mária Szekeres, György L. Nádasy, Gábor Turu, Eszter Soltész-Katona, Zsuzsanna E. Tóth, András Balla , Kevin J. Catt**, and Lászl… 
2010
2010
At present, the epidemic of overweight and obesity is one of the most pressing public health problems worldwide. Pharmacotherapy… 
Review
1999
Review
1999
The introduction of orlistat (Roche, UK) at the end of last year received considerable media coverage and was heralded in some… 
1999
1999
  • R. Wo
  • 1999
  • Corpus ID: 68484007
Sibutramine and Orlistat are suitable "supporting drugs" for use in patients trying to lose weight. Orlistat reduces the… 
1993
1993
SummaryOrlistat (tetrahydrolipstatin) reduces absorption of dietary fat by inhibiting lipases in the gastrointestinal tract… 
1988
1988
Tetrahydrolipstatin is a specific lipase inhibitor derived from lipstatin, a lipid produced by Streptomyces toxytricini In…